The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma
Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution...
Saved in:
Published in | Nuclear medicine and molecular imaging Vol. 51; no. 1; pp. 69 - 78 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.03.2017
Springer Nature B.V 대한핵의학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1869-3474 1869-3482 |
DOI | 10.1007/s13139-016-0440-y |
Cover
Loading…
Abstract | Purpose
The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC).
Methods
From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis.
Results
The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %,
p
= 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm
3
, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280,
p
= 0.001), higher SUVpeak (≥6.5, HR: 2.333,
p
= 0.020), higher SUVmean (≥3.9, HR: 2.799,
p
= 0.004), higher SUVgluc (≥8.1, HR: 2.648,
p
= 0.012), and higher TLGgluc (≥431.6, HR: 2.186,
p
= 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113,
p
= 0.005).
Conclusion
FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC. |
---|---|
AbstractList | Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. Results The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005). Conclusion FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC. Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. Results The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imagingmodalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p= 0.005). Conclusion FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC. KCI Citation Count: 3 Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. Results The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm 3 , and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005). Conclusion FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC. The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm , and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, = 0.001), higher SUVpeak (≥6.5, HR: 2.333, = 0.020), higher SUVmean (≥3.9, HR: 2.799, = 0.004), higher SUVgluc (≥8.1, HR: 2.648, = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, = 0.005). FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC. The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC).PURPOSEThe aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC).From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis.METHODSFrom December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis.The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005).RESULTSThe median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005).FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.CONCLUSIONFDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC. |
Author | Park, Hye Lim Boo, Sun Ha Kim, Hyoungwoo Lee, Yeongjoo Yoo, Ie Ryung Hyun O, Joo |
Author_xml | – sequence: 1 givenname: Yeongjoo surname: Lee fullname: Lee, Yeongjoo organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – sequence: 2 givenname: Ie Ryung surname: Yoo fullname: Yoo, Ie Ryung email: iryoo@catholic.ac.kr organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – sequence: 3 givenname: Sun Ha surname: Boo fullname: Boo, Sun Ha organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – sequence: 4 givenname: Hyoungwoo surname: Kim fullname: Kim, Hyoungwoo organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – sequence: 5 givenname: Hye Lim surname: Park fullname: Park, Hye Lim organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – sequence: 6 givenname: Joo surname: Hyun O fullname: Hyun O, Joo organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28250860$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002206177$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9kUtPGzEUha2KqkDKD-imGqkbWEzxa2zPBilKCURCaoWma8tx7iSGiZ3aE6T8-zoMIEBqvfBD_s7RvfccowMfPCD0heDvBGN5nggjrC4xESXmHJe7D-iIKFGXjCt68HKX_BCdpHSH82K0xkx-QodU0QorgY_QRbOC4jZ0UIS2mJZEFdMfV8Wvy-Z80hTOFzPfR7OCjemdLSar0Bm_dMGaaJ0Pa_MZfWxNl-Dk6Ryh39PLZnJd3vy8mk3GN6WtJO7zDhU2AlpuasOAW5UfEhYLqyRm1XxRG65YzaQRFaVMzVklREVAthwMEMtG6Gzw9bHV99bpYNzjuQz6PurxbTPThHFOJM3sxcButvM1LCzsW-j0Jrq1ibtH5dsf71bZ50FXeaBc8Gxw-mQQw58tpF6vXbLQ5d4hbJMmSjJJeS1URr-9Q-_CNvo8ikwpLIWqs-kIfX1d0UspzzFkQA6AjSGlCK22rs8jD_sCXacJ1vvM9ZC5zpnrfeZ6l5XknfLZ_H8aOmhSZv0S4qui_yn6C_Vuuw0 |
CitedBy_id | crossref_primary_10_1007_s00261_023_03908_y crossref_primary_10_1016_j_suronc_2020_06_004 crossref_primary_10_1016_j_dld_2020_08_030 crossref_primary_10_1097_MD_0000000000026015 crossref_primary_10_3748_wjg_v25_i11_1289 crossref_primary_10_1007_s00259_017_3779_0 crossref_primary_10_1016_j_suc_2024_06_001 crossref_primary_10_1007_s00261_021_03053_4 crossref_primary_10_3390_diagnostics12112889 crossref_primary_10_1007_s00259_020_05070_9 crossref_primary_10_1002_jgh3_12234 crossref_primary_10_4174_astr_2019_96_4_153 crossref_primary_10_4103_ijnm_ijnm_5_23 crossref_primary_10_1007_s00259_019_04327_2 crossref_primary_10_1097_RLU_0000000000002070 crossref_primary_10_1007_s00259_019_04558_3 crossref_primary_10_3348_kjr_2020_0689 crossref_primary_10_1148_rg_230174 crossref_primary_10_3390_cancers14205151 crossref_primary_10_1007_s00261_021_03183_9 crossref_primary_10_1007_s13139_019_00615_9 crossref_primary_10_3390_cancers15133393 crossref_primary_10_1097_RLU_0000000000002984 crossref_primary_10_1111_liv_15948 crossref_primary_10_7759_cureus_31026 crossref_primary_10_1007_s12094_018_1926_0 crossref_primary_10_1186_s13550_024_01145_y crossref_primary_10_1007_s12328_022_01712_7 crossref_primary_10_1097_MD_0000000000020932 crossref_primary_10_3390_metabo12040321 crossref_primary_10_1016_j_rcl_2021_06_001 crossref_primary_10_3389_fonc_2021_752036 crossref_primary_10_1186_s40644_020_00323_0 crossref_primary_10_1007_s13193_025_02273_0 crossref_primary_10_1016_j_cpet_2022_03_007 crossref_primary_10_1007_s13139_018_0542_9 crossref_primary_10_1007_s11307_022_01732_2 crossref_primary_10_1007_s00432_018_02832_9 crossref_primary_10_1007_s00261_024_04267_y crossref_primary_10_1097_RLU_0000000000004641 crossref_primary_10_11569_wcjd_v27_i18_1114 crossref_primary_10_1055_a_1486_3671 crossref_primary_10_1186_s12880_023_01182_4 crossref_primary_10_2967_jnumed_122_265215 crossref_primary_10_1097_RLU_0000000000003055 |
Cites_doi | 10.1016/S0140-6736(05)67530-7 10.1053/jhep.2001.25087 10.1097/00006231-200112000-00002 10.1634/theoncologist.2014-0356 10.1007/s00534-010-0293-1 10.1016/S0002-9610(02)00853-X 10.1053/jhep.2001.23912 10.1097/SLA.0b013e3182a5c985 10.1016/j.jhep.2003.11.030 10.1136/gut.48.6.816 10.1007/s13244-013-0268-2 10.1155/2014/247693 10.1097/RLU.0b013e3182867b99 10.1001/archsurg.2012.1962 10.3350/kjhep.2010.16.3.325 10.1200/JCO.2012.41.5984 10.1007/s00259-003-1297-8 10.1055/s-2004-828889 10.2214/ajr.172.1.9888743 10.1016/j.jhep.2006.03.009 10.1007/s13139-014-0269-1 10.1111/j.1572-0241.2007.01710.x 10.1136/gutjnl-2011-301748 10.1001/jamasurg.2013.5137 10.1200/JCO.2011.35.6519 10.1055/s-2004-828892 10.1007/s00259-002-0852-z 10.1007/s00259-015-3104-8 10.1007/s00330-016-4386-3 10.1186/1470-7330-14-2 |
ContentType | Journal Article |
Copyright | Korean Society of Nuclear Medicine 2016 Copyright Springer Science & Business Media 2017 |
Copyright_xml | – notice: Korean Society of Nuclear Medicine 2016 – notice: Copyright Springer Science & Business Media 2017 |
DBID | AAYXX CITATION NPM NAPCQ 7X8 5PM ACYCR |
DOI | 10.1007/s13139-016-0440-y |
DatabaseName | CrossRef PubMed Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef PubMed Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | Nursing & Allied Health Premium PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1869-3482 |
EndPage | 78 |
ExternalDocumentID | oai_kci_go_kr_ARTI_1344172 PMC5313464 28250860 10_1007_s13139_016_0440_y |
Genre | Journal Article |
GroupedDBID | --- -EM .UV 06D 0R~ 0VY 1N0 203 29~ 2KG 2VQ 30V 4.4 406 408 40D 67Z 8JR 96X 9ZL AAAVM AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH AAZMS ABAKF ABDZT ABECU ABFTV ABJNI ABJOX ABKCH ABMQK ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABXPI ACAOD ACDTI ACGFS ACHSB ACHVE ACKNC ACMDZ ACMLO ACOKC ACPIV ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGNC AEJHL AEJRE AEMSY AEOHA AEPYU AESKC AETCA AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR ANMIH AOCGG AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BGNMA CSCUP DDRTE DIK DNIVK DPUIP EBLON EBS EF. EIOEI EJD ESBYG F5P FEDTE FERAY FIGPU FINBP FNLPD FRRFC FSGXE FYJPI GGCAI GGRSB GJIRD GQ6 GQ7 H13 HF~ HMJXF HRMNR HVGLF HYE HZ~ I0C IKXTQ IWAJR IXD J-C J0Z JBSCW JZLTJ KOV LLZTM M4Y NPVJJ NQJWS NU0 O9- O9J OK1 P9S PT4 R9I RLLFE ROL RPM RSV S27 S37 S3B SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 T13 TSG U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 Z45 ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION NPM ABRTQ NAPCQ 7X8 5PM ACYCR |
ID | FETCH-LOGICAL-c570t-c5e50a6ef4a9a3e4c8a6e7eddc87035bd9a483937a652238b356651e7f4eae1c3 |
IEDL.DBID | AGYKE |
ISSN | 1869-3474 |
IngestDate | Sun Mar 09 07:51:44 EDT 2025 Thu Aug 21 17:53:37 EDT 2025 Fri Jul 11 08:48:30 EDT 2025 Wed Sep 03 00:23:48 EDT 2025 Wed Feb 19 02:42:55 EST 2025 Tue Jul 01 01:05:50 EDT 2025 Thu Apr 24 23:12:14 EDT 2025 Fri Feb 21 02:35:33 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | SUVmax Positron-Emission Tomography Intrahepatic Cholangiocarcinoma Prognosis Cholangiocarcinoma |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c570t-c5e50a6ef4a9a3e4c8a6e7eddc87035bd9a483937a652238b356651e7f4eae1c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 G704-SER000001715.2017.51.1.001 |
OpenAccessLink | https://link.springer.com/content/pdf/10.1007/s13139-016-0440-y.pdf |
PMID | 28250860 |
PQID | 1880768931 |
PQPubID | 2044329 |
PageCount | 10 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_1344172 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5313464 proquest_miscellaneous_1873724968 proquest_journals_1880768931 pubmed_primary_28250860 crossref_citationtrail_10_1007_s13139_016_0440_y crossref_primary_10_1007_s13139_016_0440_y springer_journals_10_1007_s13139_016_0440_y |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-03-01 |
PublicationDateYYYYMMDD | 2017-03-01 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
PublicationTitle | Nuclear medicine and molecular imaging |
PublicationTitleAbbrev | Nucl Med Mol Imaging |
PublicationTitleAlternate | Nucl Med Mol Imaging |
PublicationYear | 2017 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V 대한핵의학회 |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V – name: 대한핵의학회 |
References | Kim, Yun, Lee, Kim, Lee (CR24) 2003; 30 Mavros, Economopoulos, Alexiou, Pawlik (CR8) 2014; 149 CR16 Patel (CR6) 2001; 33 CR14 CR33 Feydy, Vilgrain, Denys, Sibert, Belghiti, Vullierme (CR21) 1999; 172 Kluge, Schmidt, Caca, Barthel, Hesse, Georgi (CR22) 2001; 33 Park, Kim, Kim, Jang, Moon, Lee (CR11) 2010; 16 Khan, Thomas, Davidson, Taylor-Robinson (CR1) 2005; 366 Park, Yu, Park, Cheon, Oh, Kim (CR23) 2014; 39 CR30 Taylor-Robinson, Toledano, Arora, Keegan, Hargreaves, Beck (CR4) 2001; 48 Annunziata, Caldarella, Pizzuto, Galiandro, Sadeghi, Giovanella (CR13) 2014; 2014 Albazaz, Patel, Chowdhury, Scarsbrook (CR9) 2013; 4 Kato, Tsukamoto, Kuge, Katoh, Nambu, Nobuta (CR26) 2002; 29 Kawarada, Yamagiwa, Das (CR29) 2002; 183 Khan, Davidson, Goldin, Heaton, Karani, Pereira (CR7) 2012; 61 Shaib, El-Serag (CR2) 2004; 24 Kitamura, Hatano, Higashi, Seo, Nakamoto, Narita (CR31) 2011; 18 Park, Choi, Moon, Yoo, Kim, Ahn (CR34) 2014; 14 Ribero, Pinna, Guglielmi, Ponti, Nuzzo, Giulini (CR18) 2012; 147 Wang, Li, Xia, Gong, Wang, Yan (CR17) 2013; 31 Shaib, Davila, McGlynn, El-Serag (CR5) 2004; 40 Fritscher-Ravens, Bohuslavizki, Broering, Jenicke, Schafer, Buchert (CR27) 2001; 22 Cho, Oh, Kim, Lee, Han, Im (CR32) 2015; 20 Manfredi, Barbaro, Masselli, Vecchioli, Marano (CR15) 2004; 24 Reinhardt, Strunk, Gerhardt, Roedel, Jaeger, Bucerius (CR12) 2005; 46 Jo, Won, Kim, Song, Kang, Kim (CR25) 2014; 48 Petrowsky, Wildbrett, Husarik, Hany, Tam, Jochum (CR28) 2006; 45 Kim, Kim, Lee, Hwang, Kim, Yun (CR10) 2008; 103 Sonbare (CR19) 2014; 259 de Jong, Nathan, Sotiropoulos, Paul, Alexandrescu, Marques (CR20) 2011; 29 Mouzas, Dimoulios, Vlachonikolis, Skordilis, Zoras, Kouroumalis (CR3) 2002; 22 A Fritscher-Ravens (440_CR27) 2001; 22 440_CR14 S Annunziata (440_CR13) 2014; 2014 440_CR16 T Patel (440_CR6) 2001; 33 R Albazaz (440_CR9) 2013; 4 DJ Sonbare (440_CR19) 2014; 259 R Kluge (440_CR22) 2001; 33 SA Khan (440_CR1) 2005; 366 MJ Reinhardt (440_CR12) 2005; 46 MN Mavros (440_CR8) 2014; 149 SK Park (440_CR11) 2010; 16 MC Jong de (440_CR20) 2011; 29 D Ribero (440_CR18) 2012; 147 K Kitamura (440_CR31) 2011; 18 A Feydy (440_CR21) 1999; 172 TG Park (440_CR23) 2014; 39 JY Kim (440_CR10) 2008; 103 Y Wang (440_CR17) 2013; 31 Y Kawarada (440_CR29) 2002; 183 SB Park (440_CR34) 2014; 14 R Manfredi (440_CR15) 2004; 24 H Petrowsky (440_CR28) 2006; 45 IA Mouzas (440_CR3) 2002; 22 YJ Kim (440_CR24) 2003; 30 SD Taylor-Robinson (440_CR4) 2001; 48 Y Shaib (440_CR2) 2004; 24 440_CR33 I Jo (440_CR25) 2014; 48 KM Cho (440_CR32) 2015; 20 YH Shaib (440_CR5) 2004; 40 T Kato (440_CR26) 2002; 29 SA Khan (440_CR7) 2012; 61 440_CR30 11711897 - Nucl Med Commun. 2001 Dec;22(12 ):1277-85 23358969 - J Clin Oncol. 2013 Mar 20;31(9):1188-95 26081941 - Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1984-94 22910846 - Arch Surg. 2012 Dec;147(12):1107-13 9888743 - AJR Am J Roentgenol. 1999 Jan;172(1):73-7 16690156 - J Hepatol. 2006 Jul;45(1):43-50 24955351 - Biomed Res Int. 2014;2014:247693 12095601 - Am J Surg. 2002 Jun;183(6):679-85 15123362 - J Hepatol. 2004 Mar;40(3):472-7 12552969 - Anticancer Res. 2002 Nov-Dec;22(6B):3637-41 25609313 - Cancer Imaging. 2014 Apr 22;14 :2 11343227 - Hepatology. 2001 May;33(5):1029-35 18177454 - Am J Gastroenterol. 2008 May;103(5):1145-51 11358902 - Gut. 2001 Jun;48(6):816-20 26099746 - Oncologist. 2015 Aug;20(8):926-33 24718873 - JAMA Surg. 2014 Jun;149(6):565-74 16000285 - J Nucl Med. 2005 Jul;46(7):1158-63 24335565 - Clin Nucl Med. 2014 Jan;39(1):1-7 20079127 - Chin Med J (Engl). 2009 Oct 5;122(19):2286-91 23979290 - Ann Surg. 2014 Feb;259(2):e36 21730269 - J Clin Oncol. 2011 Aug 10;29(23):3140-5 12173019 - Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1047-54 23884572 - Insights Imaging. 2013 Oct;4(5):691-700 26396641 - Nucl Med Mol Imaging. 2014 Dec;48(4):326-7 27165138 - Eur Radiol. 2017 Feb;27(2):498-506 20924217 - Korean J Hepatol. 2010 Sep;16(3):325-8 15192788 - Semin Liver Dis. 2004 May;24(2):155-64 15192785 - Semin Liver Dis. 2004 May;24(2):115-25 14579085 - Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1467-72 20503059 - J Hepatobiliary Pancreat Sci. 2011 Jan;18(1):39-46 22895392 - Gut. 2012 Dec;61(12 ):1657-69 11391522 - Hepatology. 2001 Jun;33(6):1353-7 16214602 - Lancet. 2005 Oct 8;366(9493):1303-14 |
References_xml | – volume: 366 start-page: 1303 issue: 9493 year: 2005 end-page: 14 ident: CR1 article-title: Cholangiocarcinoma publication-title: Lancet doi: 10.1016/S0140-6736(05)67530-7 – volume: 33 start-page: 1353 year: 2001 end-page: 7 ident: CR6 article-title: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States publication-title: Hepatology doi: 10.1053/jhep.2001.25087 – volume: 22 start-page: 1277 year: 2001 end-page: 85 ident: CR27 article-title: FDG PET in the diagnosis of hilar cholangiocarcinoma publication-title: Nucl Med Commun doi: 10.1097/00006231-200112000-00002 – volume: 20 start-page: 926 year: 2015 end-page: 33 ident: CR32 article-title: Metabolic Characteristics of Advanced Biliary Tract Cancer Using F-18-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications publication-title: Oncologist doi: 10.1634/theoncologist.2014-0356 – ident: CR14 – ident: CR16 – ident: CR30 – volume: 46 start-page: 1158 year: 2005 end-page: 63 ident: CR12 article-title: Detection of Klatskin’s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies publication-title: J Nucl Med – volume: 18 start-page: 39 year: 2011 end-page: 46 ident: CR31 article-title: Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer publication-title: J Hepatobiliary Pancreat Sci doi: 10.1007/s00534-010-0293-1 – volume: 183 start-page: 679 year: 2002 end-page: 85 ident: CR29 article-title: Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma publication-title: Am J Surg doi: 10.1016/S0002-9610(02)00853-X – volume: 33 start-page: 1029 year: 2001 end-page: 35 ident: CR22 article-title: Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer publication-title: Hepatology doi: 10.1053/jhep.2001.23912 – ident: CR33 – volume: 259 start-page: e36 year: 2014 ident: CR19 article-title: Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 Study Group publication-title: Ann Surg doi: 10.1097/SLA.0b013e3182a5c985 – volume: 40 start-page: 472 year: 2004 end-page: 7 ident: CR5 article-title: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? publication-title: J Hepatol doi: 10.1016/j.jhep.2003.11.030 – volume: 48 start-page: 816 year: 2001 end-page: 20 ident: CR4 article-title: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998 publication-title: Gut doi: 10.1136/gut.48.6.816 – volume: 4 start-page: 691 year: 2013 end-page: 700 ident: CR9 article-title: Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours publication-title: Insights Imaging doi: 10.1007/s13244-013-0268-2 – volume: 22 start-page: 3637 year: 2002 end-page: 41 ident: CR3 article-title: Increasing incidence of cholangiocarcinoma in Crete 1992-2000 publication-title: Anticancer Res – volume: 2014 start-page: 247693 year: 2014 ident: CR13 article-title: Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis publication-title: Biomed Res Int doi: 10.1155/2014/247693 – volume: 39 start-page: 1 year: 2014 end-page: 7 ident: CR23 article-title: Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma publication-title: Clin Nucl Med doi: 10.1097/RLU.0b013e3182867b99 – volume: 147 start-page: 1107 year: 2012 end-page: 13 ident: CR18 article-title: Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients publication-title: Arch Surg doi: 10.1001/archsurg.2012.1962 – volume: 16 start-page: 325 year: 2010 end-page: 8 ident: CR11 article-title: Detection of distant metastasis to skeletal muscle by 18F-FDG-PET in a case of intrahepatic cholangiocarcinoma publication-title: Korean J Hepatol doi: 10.3350/kjhep.2010.16.3.325 – volume: 31 start-page: 1188 year: 2013 end-page: 95 ident: CR17 article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy publication-title: J Clin Oncol doi: 10.1200/JCO.2012.41.5984 – volume: 30 start-page: 1467 year: 2003 end-page: 72 ident: CR24 article-title: Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-003-1297-8 – volume: 24 start-page: 115 year: 2004 end-page: 25 ident: CR2 article-title: The epidemiology of cholangiocarcinoma publication-title: Semin Liver Dis doi: 10.1055/s-2004-828889 – volume: 172 start-page: 73 year: 1999 end-page: 7 ident: CR21 article-title: Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings publication-title: AJR Am J Roentgenol doi: 10.2214/ajr.172.1.9888743 – volume: 45 start-page: 43 year: 2006 end-page: 50 ident: CR28 article-title: Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2006.03.009 – volume: 48 start-page: 326 year: 2014 end-page: 7 ident: CR25 article-title: Catheter Tract Implantation Metastasis Diagnosed by F-18 FDG PET/CT After Percutaneous Transhepatic Biliary Drainage for Hilar Cholangiocarcinoma publication-title: Nucl Med Mol Imaging doi: 10.1007/s13139-014-0269-1 – volume: 103 start-page: 1145 year: 2008 end-page: 51 ident: CR10 article-title: Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2007.01710.x – volume: 61 start-page: 1657 issue: 12 year: 2012 end-page: 69 ident: CR7 article-title: Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update publication-title: Gut doi: 10.1136/gutjnl-2011-301748 – volume: 149 start-page: 565 issue: 6 year: 2014 end-page: 574 ident: CR8 article-title: Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis publication-title: JAMA Surg. doi: 10.1001/jamasurg.2013.5137 – volume: 29 start-page: 3140 year: 2011 end-page: 5 ident: CR20 article-title: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.6519 – volume: 14 start-page: 2 year: 2014 ident: CR34 article-title: Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer publication-title: Cancer Imaging – volume: 24 start-page: 155 year: 2004 end-page: 64 ident: CR15 article-title: Magnetic resonance imaging of cholangiocarcinoma publication-title: Semin Liver Dis doi: 10.1055/s-2004-828892 – volume: 29 start-page: 1047 year: 2002 end-page: 54 ident: CR26 article-title: Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-002-0852-z – ident: 440_CR16 – volume: 31 start-page: 1188 year: 2013 ident: 440_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.41.5984 – volume: 29 start-page: 1047 year: 2002 ident: 440_CR26 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-002-0852-z – volume: 45 start-page: 43 year: 2006 ident: 440_CR28 publication-title: J Hepatol doi: 10.1016/j.jhep.2006.03.009 – volume: 4 start-page: 691 year: 2013 ident: 440_CR9 publication-title: Insights Imaging doi: 10.1007/s13244-013-0268-2 – volume: 46 start-page: 1158 year: 2005 ident: 440_CR12 publication-title: J Nucl Med – volume: 39 start-page: 1 year: 2014 ident: 440_CR23 publication-title: Clin Nucl Med doi: 10.1097/RLU.0b013e3182867b99 – volume: 33 start-page: 1029 year: 2001 ident: 440_CR22 publication-title: Hepatology doi: 10.1053/jhep.2001.23912 – volume: 22 start-page: 3637 year: 2002 ident: 440_CR3 publication-title: Anticancer Res – volume: 18 start-page: 39 year: 2011 ident: 440_CR31 publication-title: J Hepatobiliary Pancreat Sci doi: 10.1007/s00534-010-0293-1 – volume: 16 start-page: 325 year: 2010 ident: 440_CR11 publication-title: Korean J Hepatol doi: 10.3350/kjhep.2010.16.3.325 – volume: 30 start-page: 1467 year: 2003 ident: 440_CR24 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-003-1297-8 – volume: 366 start-page: 1303 issue: 9493 year: 2005 ident: 440_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(05)67530-7 – volume: 149 start-page: 565 issue: 6 year: 2014 ident: 440_CR8 publication-title: JAMA Surg. doi: 10.1001/jamasurg.2013.5137 – volume: 183 start-page: 679 year: 2002 ident: 440_CR29 publication-title: Am J Surg doi: 10.1016/S0002-9610(02)00853-X – volume: 48 start-page: 816 year: 2001 ident: 440_CR4 publication-title: Gut doi: 10.1136/gut.48.6.816 – ident: 440_CR33 doi: 10.1007/s00259-015-3104-8 – volume: 103 start-page: 1145 year: 2008 ident: 440_CR10 publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2007.01710.x – volume: 29 start-page: 3140 year: 2011 ident: 440_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.6519 – volume: 24 start-page: 115 year: 2004 ident: 440_CR2 publication-title: Semin Liver Dis doi: 10.1055/s-2004-828889 – volume: 24 start-page: 155 year: 2004 ident: 440_CR15 publication-title: Semin Liver Dis doi: 10.1055/s-2004-828892 – volume: 40 start-page: 472 year: 2004 ident: 440_CR5 publication-title: J Hepatol doi: 10.1016/j.jhep.2003.11.030 – volume: 172 start-page: 73 year: 1999 ident: 440_CR21 publication-title: AJR Am J Roentgenol doi: 10.2214/ajr.172.1.9888743 – volume: 2014 start-page: 247693 year: 2014 ident: 440_CR13 publication-title: Biomed Res Int doi: 10.1155/2014/247693 – volume: 48 start-page: 326 year: 2014 ident: 440_CR25 publication-title: Nucl Med Mol Imaging doi: 10.1007/s13139-014-0269-1 – volume: 33 start-page: 1353 year: 2001 ident: 440_CR6 publication-title: Hepatology doi: 10.1053/jhep.2001.25087 – ident: 440_CR14 doi: 10.1007/s00330-016-4386-3 – volume: 61 start-page: 1657 issue: 12 year: 2012 ident: 440_CR7 publication-title: Gut doi: 10.1136/gutjnl-2011-301748 – ident: 440_CR30 – volume: 259 start-page: e36 year: 2014 ident: 440_CR19 publication-title: Ann Surg doi: 10.1097/SLA.0b013e3182a5c985 – volume: 14 start-page: 2 year: 2014 ident: 440_CR34 publication-title: Cancer Imaging doi: 10.1186/1470-7330-14-2 – volume: 22 start-page: 1277 year: 2001 ident: 440_CR27 publication-title: Nucl Med Commun doi: 10.1097/00006231-200112000-00002 – volume: 20 start-page: 926 year: 2015 ident: 440_CR32 publication-title: Oncologist doi: 10.1634/theoncologist.2014-0356 – volume: 147 start-page: 1107 year: 2012 ident: 440_CR18 publication-title: Arch Surg doi: 10.1001/archsurg.2012.1962 – reference: 27165138 - Eur Radiol. 2017 Feb;27(2):498-506 – reference: 15192785 - Semin Liver Dis. 2004 May;24(2):115-25 – reference: 23358969 - J Clin Oncol. 2013 Mar 20;31(9):1188-95 – reference: 14579085 - Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1467-72 – reference: 23979290 - Ann Surg. 2014 Feb;259(2):e36 – reference: 11343227 - Hepatology. 2001 May;33(5):1029-35 – reference: 23884572 - Insights Imaging. 2013 Oct;4(5):691-700 – reference: 11358902 - Gut. 2001 Jun;48(6):816-20 – reference: 24955351 - Biomed Res Int. 2014;2014:247693 – reference: 9888743 - AJR Am J Roentgenol. 1999 Jan;172(1):73-7 – reference: 12552969 - Anticancer Res. 2002 Nov-Dec;22(6B):3637-41 – reference: 24718873 - JAMA Surg. 2014 Jun;149(6):565-74 – reference: 26099746 - Oncologist. 2015 Aug;20(8):926-33 – reference: 11391522 - Hepatology. 2001 Jun;33(6):1353-7 – reference: 16214602 - Lancet. 2005 Oct 8;366(9493):1303-14 – reference: 18177454 - Am J Gastroenterol. 2008 May;103(5):1145-51 – reference: 16690156 - J Hepatol. 2006 Jul;45(1):43-50 – reference: 25609313 - Cancer Imaging. 2014 Apr 22;14 :2 – reference: 15123362 - J Hepatol. 2004 Mar;40(3):472-7 – reference: 20079127 - Chin Med J (Engl). 2009 Oct 5;122(19):2286-91 – reference: 21730269 - J Clin Oncol. 2011 Aug 10;29(23):3140-5 – reference: 15192788 - Semin Liver Dis. 2004 May;24(2):155-64 – reference: 12095601 - Am J Surg. 2002 Jun;183(6):679-85 – reference: 12173019 - Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1047-54 – reference: 22910846 - Arch Surg. 2012 Dec;147(12):1107-13 – reference: 20924217 - Korean J Hepatol. 2010 Sep;16(3):325-8 – reference: 26396641 - Nucl Med Mol Imaging. 2014 Dec;48(4):326-7 – reference: 26081941 - Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1984-94 – reference: 11711897 - Nucl Med Commun. 2001 Dec;22(12 ):1277-85 – reference: 16000285 - J Nucl Med. 2005 Jul;46(7):1158-63 – reference: 24335565 - Clin Nucl Med. 2014 Jan;39(1):1-7 – reference: 20503059 - J Hepatobiliary Pancreat Sci. 2011 Jan;18(1):39-46 – reference: 22895392 - Gut. 2012 Dec;61(12 ):1657-69 |
SSID | ssj0000329037 |
Score | 2.2702737 |
Snippet | Purpose
The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic... The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma... Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic... |
SourceID | nrf pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 69 |
SubjectTerms | Cardiology Computed tomography Diagnostic software Diagnostic systems Fluorine Glucose Glycolysis Imaging Magnetic resonance imaging Mathematical analysis Medical prognosis Medicine Medicine & Public Health Metabolism Metastasis Nuclear Medicine Oncology Original Original Article Orthopedics Patients Positron emission Radioisotopes Radiology Regional analysis Regression analysis Survival Tomography 방사선과학 |
Title | The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma |
URI | https://link.springer.com/article/10.1007/s13139-016-0440-y https://www.ncbi.nlm.nih.gov/pubmed/28250860 https://www.proquest.com/docview/1880768931 https://www.proquest.com/docview/1873724968 https://pubmed.ncbi.nlm.nih.gov/PMC5313464 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002206177 |
Volume | 51 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Nuclear Medicine and Molecular Imaging , 2017, 51(1), , pp.69-78 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED_RTkK8AOMzsFUG8QTKlsRO4rwgdd2yDbQJoVYaT5bjOFvVkaCufRh_PXdp0q5jIO0lUeRzZPvu4rvc-XcAH3w_k1FhcldEUriCZ7FLVohrUJgDsufDiA4nn5xGRyPx5Sw8a85xX7XZ7m1Isv5Srw67cbRW0PVFD5gCktcd2Ah9mcgubPQPf3xd_VrxeJB4NVom1VtyuYhFG8-86z1rO1KnnBZ3GZt_50zeCpzW-1H6BIbtTBZpKJOd-SzbMb9vgTzec6pP4XFjn7L-QqA24YEtn8HDkyYC_xw-o1yx79WlZVXBUteXLN0_ZN8OhruDIRuX7JjGfWEpT9uwATnO5fkY98spdq9-6hcwSg-GgyO3qcHgmjD2Zni1oacjWwidaG6FkfgQ2zw3qOg8zPJEC0mgejpCS47LDJkbhb6NC2G19Q1_Cd2yKu1rYHmIvp1NtGcIVy2zMvd4IXLtxUXI40I64LV8UKYBKKc6GZdqBa1M66IoKY3WRV078HHZ5dcCneN_xO-RuWpixoowtel-XqnJVKHncKx8TsXYAge2Wt6rRpuvFGHWoVuWcN-Bd8tm1EMKrujSVnOioYI_IolwHq8WorIcEp0PRtfRcyBeE6IlAY1nvaUcX9RY3_iJ5CISDnxqJeXGsP410zf3on4LjwKyVerEui3ozqZzu42W1izroWale3unvUbDetAZBf0_k_UdpQ |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-xIQEvaHwHNjCIJ1A0J3Yc5wVp6lZaWCeEWmlvluM4W7WRoK572H_PXZpklA0kXhJFthPb54_f5c6_A3gfRblWpStCqbQMpcjTkFBI6HAwx4TnE0WHkydHajSTX46T4_Yc90Xn7d6ZJJuV-vqwm0C0gqovasBkkLzagLuIBTSFLZjFe_2PFS7ijDdcmRRtKRQylZ0187a3rO1HG9WivA1q3vSY_MNs2uxGwy142MJItreS-yO446vHcG_SGsqfwCcUP_ten3tWl2wYRpoN9z-zbwfT3cGUzSs2pg-cenKndmxA-m11MsdtbYHF6x_2KcyGB9PBKGxDJYQuSfkSrz7hVvlS2swKL53Gh9QXhcP5KJK8yKzUxH1nFQIuoXOUgUoin5bSWx858Qw2q7ryL4AVCapgPrPcEf1Z7nXBRSkLy9MyEWmpA-BdhxnX8ohTOItzc82ATH1syHeM-thcBfChL_JzRaLxr8zvUArmzM0NUV_T_aQ2ZwuDAH9sIkEx0-IAtjshmXbSXRiilkPtKRNRAG_7ZJwuZAOxla8vKQ_F5ZGZwnY8X8m0rxId40UNjweQrkm7z0D1WU-p5qcNJTeuZEIqGcDHblz8Vq2_tfTlf-V-A_dH08mhORwffX0FD2KCF40v3DZsLheXfgfB0TJ_3UyGX9VNAR0 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwEB3RIlVcEN8EChjECRRtEjtOckGqtg1doFWFdqXeLMex21WLU223h_57ZrJJykJB4pIosZM4nnH8JjN-A_A-jqtcOlOHQuYiFLzKQkIhoUFlTgjPp5IWJx8cyv2Z-HKcHnd5Ti_7aPfeJbla00AsTX45uqjd6GbhG0fkgmYwWsPknLzegLuCzqFCz5Kd4SdLxJMiankzKfNSyEUmes_mbXdZm5s2_MLdBjv_jJ78zYXazkzlA7jfQUq2s9KBh3DH-kewddA5zR_DJ1QF9r05t6xxrAzjnJW7n9nR3nQ0nrK5ZxN6wKml0GrDxmTr-pM5TnELvLz5oZ_ArNybjvfDLm1CaNIsWuLWppGW1gldaG6FyfEgs3VtcGzytKoLLXLiwdMSwRfPK5SHTGObOWG1jQ1_Cpu-8fY5sDpFc8wWOjJEhVbZvI64E7WOMpfyzOUBRH2HKdNxilNqi3N1w4ZMfawojoz6WF0H8GG45GJFqPGvyu9QCurMzBXRYNP-pFFnC4Vgf6JiTvnTkgC2eyGpbgBeKqKZQ0uq4HEAb4diHDrkD9HeNldUh3L0iELiezxbyXRoEi3pRWsvCiBbk_ZQgdqzXuLnpy09N37VuJAigI-9XvzSrL-96Yv_qv0Gto52S_Vtcvj1JdxLCGm0YXHbsLlcXNlXiJOW1et2LPwEpT4FWQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Role+of+F-18+FDG+PET%2FCT+in+Intrahepatic+Cholangiocarcinoma&rft.jtitle=Nuclear+medicine+and+molecular+imaging&rft.au=Lee%2C+Yeongjoo&rft.au=Yoo%2C+Ie+Ryung&rft.au=Boo%2C+Sun+Ha&rft.au=Kim%2C+Hyoungwoo&rft.date=2017-03-01&rft.issn=1869-3474&rft.volume=51&rft.issue=1&rft.spage=69&rft_id=info:doi/10.1007%2Fs13139-016-0440-y&rft_id=info%3Apmid%2F28250860&rft.externalDocID=28250860 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1869-3474&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1869-3474&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1869-3474&client=summon |